{CMRX US Equity DES<Go>}
Chimerix down 79% at all time low premarket after brincidofovir misses primary endpoint of preventing CMV infection after HCT
Chimerix down 79% at all time low premarket after brincidofovir misses primary endpoint of preventing CMV infection after HCT
- Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant.
- Mgmt does not yet understand the difference between Phase 2 and SUPPRESS data.
- Chimerix plans to continue the programs testing brincidofovir in serious adenovirus infections and in smallpox.
- Pending the availability of complete data from SUPPRESS, including secondary endpoints in other dsDNA viral infections (full data will be presented Feb 18-22), Chimerix has elected to pause further enrollment in the Phase 3 SUSTAIN and SURPASS trials in kidney transplant recipients -- out of caution.
- CMRX is down 78% at an all-time low as brincidofovir is CMRX's lead product candidate.